NtaiosGMichelP.Temporal distribution and magnitude of the vulnerability period around stroke depend on stroke subtype. Cerebrovasc Dis2011; 32: 246–253.
2.
SharmaMHartRGConnollySJ, et al. Stroke outcomes in the COMPASS trial. Circulation2019; 139: 1134–1145.
3.
AdamouAPapadimitriouDStramboDKorompokiEMichelPNtaiosG.Efficacy and safety of addition of oral anticoagulant to standard antiplatelet treatment in patients with ischemic stroke and no indication for oral anticoagulation: systematic review and meta-analysis. Int J Stroke2025; 20: 776–785.
4.
MarkusHS.Exercise to prevent stroke and dementia-world stroke day 2024. Int J Stroke2024; 19: 960–961.
5.
HobeanuCLavalléePCCharlesH, et al. Risk of subsequent disabling or fatal stroke in patients with transient ischaemic attack or minor ischaemic stroke: an international, prospective cohort study. Lancet Neurol2022; 21: 889–898.
6.
CowanLTTomeJMallhiAK, et al. Changes in physical activity and risk of ischemic stroke: the ARIC study. Int J Stroke2023; 18: 173–179.
7.
FiniNAHollandAEKeatingJ, et al. How physically active are people following stroke? Systematic review and quantitative synthesis. Phys Ther2017; 97: 707–717.
8.
BrauerSGKuysSSAdaLParatzJD.IMproving physical activity after stroke via treadmill training (IMPACT) and self-management: a randomized trial. Int J Stroke2022; 17: 1137–1144.
9.
ThurstonCHumphriesSBezuidenhoutL, et al. Mobile health delivered physical activity after mild stroke or transient ischemic attack: is it feasible and acceptable?Int J Stroke2025; 20: 801–811.
10.
EnglishCRamageERAttiaJ, et al. Secondary prevention of stroke: a telehealth-delivered physical activity and diet pilot randomized trial (enable-pilot). Int J Stroke2024; 19: 198–208.
11.
Parry-JonesARKrishnamurthiRZiaiWC, et al. Stroke organization (WSO): global intracerebral hemorrhage factsheet 2025. Int J Stroke2025; 20: 145–150.
12.
SeiffgeDJAndersonCS.Treatment for intracerebral hemorrhage: dawn of a new era. Int J Stroke2024; 19: 482–489.
13.
Parry-JonesARSammut-PowellCParoutoglouK, et al. An intracerebral hemorrhage care bundle is associated with lower case fatality. Ann Neurol2019; 86: 495–503.
14.
MaLHuXSongL, et al. The third intensive care bundle with blood pressure reduction in acute cerebral haemorrhage trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial. Lancet2023; 402: 27–40.
15.
Apostolaki -HanssonTOuyangM, et al. International care bundle evaluation in cerebral hemorrhage research (I-CATCHER): study protocol for a multicenter, batched, parallel, cluster-randomized trial with a baseline period. Int J Stroke2025; 20: 891–897.
16.
Al-Shahi SalmanRFrantziasJLeeRJ, et al. Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. Lancet Neurol2018; 17: 885–894.
17.
ConnollySJSharmaMCohenAT, et al. Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage. N Engl J Med2024; 390: 1745–1755.
18.
BukaRJ.Andexanet alfa: trials just leave us with more questions. Res Pract Thromb Haemost2025; 9: e102628.
19.
DienerHCKuklikNHüsingA, et al. Andexanet Alfa in patients with factor Xa inhibitor-associated intracranial hemorrhage: the prospective observational multicenter ASTRO-DE study. Int J Stroke2025; 20: 831–842.
20.
LeeHSSohnMKLeeJ, et al. Long-term functional outcomes among patients surviving aneurysmal subarachnoid hemorrhage: the KOSCO study. Int J Stroke2025; 20: 821–830.
21.
EwbankFHallSGaastraBBultersD.Acetylsalicylic acid and subarachnoid hemorrhage in the nurses’ health study. Int J Stroke2025; 20: 812–820.
